Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment

Sandra P Smieszek, Bart P Przychodzen, Mihael H Polymeropoulos, Sandra P Smieszek, Bart P Przychodzen, Mihael H Polymeropoulos

Abstract

SARS-coronavirus 2 is the causal agent of the COVID-19 outbreak. SARS-Cov-2 entry into a cell is dependent upon binding of the viral spike (S) protein to cellular receptor and on cleavage of the spike protein by the host cell proteases such as Cathepsin L and Cathepsin B. CTSL/B are crucial elements of lysosomal pathway and both enzymes are almost exclusively located in the lysosomes. CTSL disruption offers potential for CoVID-19 therapies. The mechanisms of disruption include: decreasing expression of CTSL, direct inhibition of CTSL activity and affecting the conditions of CTSL environment (increase pH in the lysosomes). We have conducted a high throughput drug screen gene expression analysis to identify compounds that would downregulate the expression of CTSL/CTSB. One of the top significant results shown to downregulate the expression of the CTSL gene is amantadine (10uM). Amantadine was approved by the US Food and Drug Administration in 1968 as a prophylactic agent for influenza and later for Parkinson's disease. It is available as a generic drug. Amantadine in addition to downregulating CTSL appears to further disrupt lysosomal pathway, hence, interfering with the capacity of the virus to replicate. It acts as a lysosomotropic agent altering the CTSL functional environment. We hypothesize that amantadine could decrease the viral load in SARS-CoV-2 positive patients and as such it may serve as a potent therapeutic decreasing the replication and infectivity of the virus likely leading to better clinical outcomes. Clinical studies will be needed to examine the therapeutic utility of amantadine in COVID-19 infection.

Copyright © 2020 Elsevier Ltd. All rights reserved.

Figures

Fig. 1
Fig. 1
Notable difference in over-representation of genes with downregulated expression across lysosome pathway genes. Black columns represent average expression levels of amantadine treated samples, gray columns represent average expression levels of control samples. Y-axis represents Affymetrix probe intensity associated with expression.
Fig. 2
Fig. 2
Normalized Expression of Cathepsin L (CTSL) across tissues between females (red) and males (blue) log10(TPM) (x-axis log10 of Transcripts per Million, plus one).

References

    1. Zhu N. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733.
    1. Yan R. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020 doi: 10.1126/science.abb2762.
    1. Hadfield J. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018;34:4121–4123.
    1. Hoffmann M. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;0
    1. Lonsdale J. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 2013;45:580–585.
    1. Wrapp D. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263.
    1. Simmons G. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. 2005;102:11876–11881.
    1. Elshabrawy H.A. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay. J. Virol. 2014;88:4353–4365.
    1. Kirschke H., Cathepsin L. Handb. Proteolytic Enzym. 1808–1817. 2013 doi: 10.1016/B978-0-12-382219-2.00410-5.
    1. Matsuyama S. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J. Virol. 2010;84:12658–12664.
    1. Herst C. An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design. bioRxiv. 2020 doi: 10.1101/2020.02.25.963546. 2020.02.25.963546.
    1. Takahashi Y., Haga S., Ishizaka Y., Mimori A. Autoantibodies to angiotensin-converting enzyme 2 in patients with connective tissue diseases. Arthritis Res. Ther. 2010;12:R85.
    1. Krammer F. Influenza. Nat. Rev. Dis. Prim. 2018;4:1–21.
    1. Kolocouris A. Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A. J. Med. Chem. 2014;57:4629–4639.
    1. Ma C. Identification of the functional core of the influenza A virus A/M2 proton-selective ion channel. Proc. Natl. Acad. Sci. U. S. A. 2009;106:12283–12288.
    1. Pisonero-Vaquero S., Medina D.L. Lysosomotropic Drugs: Pharmacological Tools to Study Lysosomal Function. Curr. Drug Metab. 2018;18:1147–1158.
    1. Duff K.C., Cudmore A.J., Bradshaw J.P. The location of amantadine hydrochloride and free base within phospholipid multilayers: a neutron and X-ray diffraction study. Biochim. Biophys. Acta - Biomembr. 1993;1145:149–156.
    1. deVries T., Dentiste A., Handiwala L., Jacobs D. Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies. Neurol. Ther. 2019;8:449–460.
    1. Smedley D. The BioMart community portal: an innovative alternative to large, centralized data repositories. Nucleic Acids Res. 2015;43:W589–W598.
    1. Mbewe-Campbell N. Genes and environment: novel, functional polymorphism in the human cathepsin L (CTSL1) promoter disrupts a xenobiotic response element (XRE) to alter transcription and blood pressure. J. Hypertens. 2012;30:1961–1969.
    1. Karczewski K.J. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv. 2019 doi: 10.1101/531210.
    1. Hindson J. COVID-19: faecal–oral transmission? Nat. Rev. Gastroenterol. Hepatol. 2020 doi: 10.1038/s41575-020-0295-7. pp. 1–1.
    1. Withrock I.C. Genetic diseases conferring resistance to infectious diseases. Genes Dis. 2015;2:247–254.
    1. Haines K.M., Vande Burgt N.H., Francica J.R., Kaletsky R.L., Bates P. Chinese hamster ovary cell lines selected for resistance to ebolavirus glycoprotein mediated infection are defective for NPC1 expression. Virology. 2012;432:20–28.
    1. Takadate Y. Niemann-Pick C1 Heterogeneity of Bat Cells Controls Filovirus Tropism. Cell Rep. 2020;30:308–319.e5.
    1. Polymeropoulos M.H. Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia. Schizophr. Res. 2009;108:134–142.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit